Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Esophageal Neoplasms 2Ovarian Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Fluorouracil 12pembrolizumab 9Oxaliplatin 9Nivolumab 9Leucovorin 8Capecitabine 7Cisplatin 6Trastuzumab 4Paclitaxel 3Drug Therapy 3Docetaxel 3zimberelimab 2zanidatamab 2tucatinib 2spartalizumab 2durvalumab 2Radiotherapy 2Levoleucovorin 2Irinotecan 2Gemcitabine 2Carboplatin 2130-nm albumin-bound paclitaxel 2zolbetuximab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tezacitabine 1ribociclib 1quemliclustat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma Of Esophagus × matuzumab × Clear all
NCT00113581 2014-02-19

Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡